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Abstract 
The SARS-CoV-2 lineage B.1.1.7, now designated Variant of Concern 202012/01 (VOC) by 
Public Health England, originated in the UK in late Summer to early Autumn 2020. We examine 
epidemiological evidence for this VOC having a transmission advantage from several 
perspectives. First, whole genome sequence data collected from community-based diagnostic 
testing provides an indication of changing prevalence of different genetic variants through time. 
Phylodynamic modelling additionally indicates that genetic diversity of this lineage has changed 
in a manner consistent with exponential growth. Second, we find that changes in VOC 
frequency inferred from genetic data correspond closely to changes inferred by S-gene target 
failures (SGTF) in community-based diagnostic PCR testing. Third, we examine growth trends in 
SGTF and non-SGTF case numbers at local area level across England, and show that the VOC 
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has higher transmissibility than non-VOC lineages, even if the VOC has a different latent period 
or generation time. Available SGTF data indicate a shift in the age composition of reported 
cases, with a larger share of under 20 year olds among reported VOC than non-VOC cases. 
Fourth, we assess the association of VOC frequency with independent estimates of the overall 
SARS-CoV-2 reproduction number through time. Finally, we fit a semi-mechanistic model 
directly to local VOC and non-VOC case incidence to estimate the reproduction numbers over 
time for each. There is a consensus among all analyses that the VOC has a substantial 
transmission advantage, with the estimated difference in reproduction numbers between VOC 
and non-VOC ranging between 0.4 and 0.7, and the ratio of reproduction numbers varying 
between 1.4 and 1.8. We note that these estimates of transmission advantage apply to a period 
where high levels of social distancing were in place in England; extrapolation to other 




A novel SARS-CoV-2 lineage, originally termed variant B.1.1.7, is rapidly expanding its 
geographic range and frequency in England. The lineage was detected in November 2020, and 
likely originated in September 2020 in the South East region of England. As of 20 December 
2020, the regions in England with the largest numbers of confirmed cases of the variant are 
London, the South East, and the East of England. The variant possesses a large number of 
non-synonymous substitutions of immunologic significance ​1​. The N501Y replacement on the 
spike protein has been shown to increase ACE2 binding ​2,3​ and cell infectivity in animal models​4​, 
while the P618H replacement on the spike proteins adjoins the furin-cleavage site ​5​. The variant 
also possesses a deletion at positions 69 and 70 of the spike protein (Δ69-70) which has been 
associated with diagnostic test failure for the ThermoFisher TaqPath probe targeting the spike 
protein ​6​. Whilst other variants with Δ69-70 are also circulating in the UK, the absence of 
detection of the S gene target in an otherwise positive PCR test increasingly appears to be a 
highly specific marker for the B.1.1.7 lineage. Surveillance data from national community testing 
(“Pillar 2”) showed a rapid increase in S-gene target failures (SGTF) in PCR testing for 
SARS-CoV-2 in November and December 2020, and the B.1.1.7 lineage has now been 
designated Variant of Concern (VOC) 202012/01 by Public Health England (PHE).  
 
Phylogenetic studies carried out by the UK COVID-19 Genomics Consortium (COG-UK)​7 
provided the first indication that the VOC has an unusual accumulation of substitutions and was 
growing at a large rate relative to other circulating lineages. Here we analyse VOC whole 
genomes collected between October and 5 December 2020 and find that the rate of increase in 
the frequency of VOC is consistent with a transmission advantage over other circulating 
lineages in the UK. To substantiate these findings, we investigate time trends in the proportion 
of PCR tests exhibiting SGTF across the UK on ~275,000 test results as a biomarker of VOC 
infection, and examine the relationship between local epidemic growth and the frequency of the 
VOC. We demonstrate that increasing reproduction numbers (‘R’ values) are associated with 
increased SGTF frequency among reported cases, our biomarker of VOC infection, and confirm 
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this association through a variety of analytical approaches. Critically, we find evidence that 
non-pharmaceutical interventions (NPIs) were sufficient to control non-VOC lineages to 
reproduction numbers below 1 during the November 2020 lockdown in England, but that at the 
same time the NPIs were insufficient to control the VOC. 
 
 
Origins and expansion of VOC 202012/01 
 
We examined the time and location of sampling of 1,904 VOC whole genomes collected 
between October and 5 December 2020, combined with a genetic background of 48,128 
genomes collected over the same period. Sequences of the VOC were widely distributed across 
199 lower tier local authorities (LTLAs) in England, but highly concentrated in the South East 
(n=875), London (n=636) and East of England (n=293). Relative to this genetic background, the 
growth of the VOC lineage is consistent with it having a selective advantage over circulating 
SARS-CoV-2 variants in England (Figure 1A). While rapid growth of the variant was first 
observed in the South East, similar growth patterns are observed later in London, East of 
England, and now more generally across England. Across these regions, we estimate similar 
growth differences between the VOC and non-VOC lineages of +49% to 53% per generation 
(Supporting Table S1) by fitting a logistic growth model to the frequency of VOC sequence 
samples through time and adjusting for an approximate mean generation time of SARS-CoV-2 
of 6.5 days (see Supporting Methods) ​8​,​9​. 
 
S gene target failure in SARS-CoV-2 testing as a biomarker for the VOC 
 
The UK has a high throughput national testing system for community cases, based in a small 
number of large laboratories. We were able to extend our genomic analyses to epidemiologic 
case data, because the VOC lineage is not detected in the S-gene target in an otherwise 
positive PCR test (ThermoFisher TaqPath as performed in the UK national testing system). 
Several SARS-CoV-2 variants can result in SGTF, but since mid-November, more than 97% of 
Pillar 2 PCR tests showing SGTF are due to the VOC lineage ​10​. Before mid-November 2020, 
the frequency of SGTF among PCR positives was a poorer proxy for frequency of the VOC. We 
therefore developed a Gaussian Markov Random Field model (see Supplementary Information, 
Figure S1)  to predict the proportion of SGTF cases attributable to the VOC lineage by area and 
week, here termed the true positive rate (TPR), and the number of SGTF cases attributable to 
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Trends in SARS-CoV-2 cases with S gene target failure that are attributed to the VOC 
 
SGTF data were available for 35% of Pillar 2 positive test results between November 26 to 
December 13, 2020. Given the greater abundance of SGTF data, a more detailed picture of the 
VOC frequency over time can be discerned after our TPR adjustments. Overall, empirical and 
estimated frequencies of TPR-adjusted SGTF cases show a similar pattern of expansion as 
frequencies estimated from genetic data in terms of time, region, and rate of growth (Figure 1D). 
As of December 13, SGTF is detected in all regions of England (Figure S2), and the estimated 
frequency of TPR-adjusted SGTF ranges from 15% in Yorkshire and the Humber to 85% in the 
South East, where the VOC was first detected. Changes in COVID-19 infections correlate with 
raw (not adjusted for TPR) SGTF cases on a regional basis. Figures 2 and S3 shows the time 
trends of SGTF (S-) cases, S-gene positive cases (S+) and total PCR positive cases by NHS 
England Sustainability and Transformation Plan (STP) areas (a geographic subdivision of NHS 
Regions). Visually, it is clear that while lockdown successfully controlled S+ cases in virtually 
every STP, S- case numbers increased during lockdown. 
 
 
Figure 1. Expansion and growth of the VOC ​202012/01 ​ lineage. A) The number of UK LTLAs 
reporting at least one sampled VOC genome. B) Empirical (solid) and estimated (dash) 
frequency of TPR-adjusted SGTF in three regions of England. C) Empirical (points) and 
estimated (line) frequency (log odds) of VOC inferred from genomic data by epidemiological 
week. D) Empirical (points) and estimated (line) frequency (log odds) of SGTF based on the 
same data as B. 
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Figure 2. Case trends in a subset of NHS STP areas. Total cases reported are shown as a thick 
line. A subset of these - those tested in the 3 largest “Lighthouse” laboratories - were tested for 
SGTF. The total cases line is coloured according to percentage S- among those tested. Counts of 
S+ and S- reported via the PHE SGSS system are shown by the thin lines. The dates of the second 
lockdown are indicated by the vertical red lines. Nine representative NHS STP areas from all 
regions of England are ordered by decreasing percentage S- in the most recent week of data. Raw 
SGTF data are shown here (not adjusted for TPR), so S- cases in earlier weeks include other 
non-VOC lineages, especially outside the East and South East of England. Plots for all STP areas 
are shown in Figure S3. 
 
Transmission advantage of the VOC 
 
To examine the differences between S- and S+ growth rates, we focus on epidemiological 
weeks 46-50 (8th November-12th December). We estimate the total S- and S+ in each STP and 
week by adjusting counts upwards in proportion to total cases reported in each STP and week. 
We then calculate the week on week growth factor in both S- and S+ cases by dividing the case 
numbers in week ​t+1 ​ by the case numbers in week ​t​. Given an assumed mean generation time 
of SARS-CoV-2 of 6.5 days​9​, we correct these weekly growth factors by raising them to the 
power of to ensure they can be interpreted as approximate reproduction numbers. For each7
6.5  
STP and week, we compute both the ratio and difference of the resulting empirical reproduction 
number of the S-negative cases to that of the S-positive cases (Figure 3). Overall, the median 
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multiplicative advantage is 1.74 for the VOC, and the median additive advantage is 0.63, 
showing a clear advantage of the VOC for both metrics. 
 
 
Figure 3. Empirical data analysis of the advantage in weekly growth factors (cases in week t+1 
divided by cases in week t) for the VOC versus non-VOC lineages. Each point represents either 
the ratio (left) or difference (right) of weekly growth factors for the VOC versus non-variant for an 
NHS England STP area and week, using the raw SGTF data shown in Figure S1 (not correcting for 
TPR). Colours and shapes differentiate epi weeks. Numbers above 1 on the top plot and above 0 
on the bottom plot show a transmission advantage. The blue line represents the mean advantage 
for a particular proportion of VOC among all cases, and the grey lines the 95% envelope. Scatter 
at low frequencies largely reflects statistical noise due to low counts. 
 
 
Paired growth rate trends of the VOC and non-VOC lineages demonstrate an increase in the 
reproduction number 
 
We next tested the hypothesis that the higher growth rates of the VOC compared to other 
circulating lineages might be due solely to shorter generation times (e.g. a shorter incubation 
period), rather than increased  transmissibility (R). To this end, we compared the number of 
NHS STP areas in which both VOC and non-VOC cases increased or decreased (Table 1). If 
the VOC had the same reproduction number as non-VOC but a shorter generation time, VOC 
cases are expected to grow faster than non-VOC cases in areas where non-VOC grew. 
However VOC cases are expected to ​decline ​ faster than non-VOC cases where non-VOC 
declined. Furthermore, areas where VOC grew but non-VOC declined would, on average, be 
equally balanced by areas where the opposite was true. That is, if only the generation interval of 
the VOC had shortened , the proportion of areas with positive growth of the VOC and negative 
growth of the non-VOC would be highly correlated with the proportion of areas with negative 
growth of the VOC and positive growth of the non-VOC. However, of 168 STP-weeks (42 STP 
areas, weekly growth factors for weeks 46-49) there were 97 STP-weeks where growth was 
observed in S- and decline was observed in S+, but only 1 STP-week where the opposite was 
true (Table 1), indicating strong evidence against S+ and S- reproduction numbers being equal 
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(McNemar’s Chi-square test with continuity correction test statistic 92.02, ​p ​ < 1e-15). Comparing 
the empirical distribution of growth factors from S+ and S- with the nonparametric 
Kolmogorov–Smirnov test results in rejecting the null hypothesis ( ​p ​ < 1e-15) that the two arise 
from the same probability distribution. 
 
Table 1. Contingency table of VOC and non-VOC weekly growth factors derived from raw SGTF 
data within 42 NHS STP areas for weeks 46-49, stratified by increasing (>1) and declining 
incidence( . The imbalance in off-diagonal elements gives strong evidence of increased)≤ 1  
transmissibility, even if the VOC had an altered generation time distribution. 
 
 
Share of age groups among VOC and non-VOC cases 
 
To assess differences in the age distribution of VOC versus non-VOC cases, we considered S- 
and S+ case numbers in weeks 46-51 across NHS STP regions. Case numbers were 
standardised for differences in the population age composition in each area, weighted to 
compare S- cases from each NHS STP region and each epidemiological week with an equal 
number of S+ cases from that same STP and week (a case-control design), and aggregated 
over STP weeks. Accounting for binomial sampling variation and variation by area and week, 
we observe significantly more S- cases, our biomarker of VOC cases, among individuals aged 
0-19 as compared to S+ cases, and significantly fewer S- cases among individuals aged 60-79 
(Figure 4). This trend is seen in each of the regions of England most affected by the VOC thus 
far (East of England, London, South East and Midlands), and similar differences are seen 
between the raw (non-case control weighted, and non-age-standardised) age distributions of S+ 
and S- cases.  
 
 
 OC  V > 1  OC  V ≤ 1  
on OC  n − V > 1  34 1 
on OC  n − V ≤ 1  97 36 
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Figure 4. Age distribution of S-gene negative (S-) and S-gene positive (S+) PCR-positive pillar 2 
cases from the SGSS dataset (not adjusted for TPR). Case numbers are weighted to compare S- 
cases from each NHS STP region and epidemiological week with an equal number of S+ cases 
from that STP and week (a case-control design), and standardised for differences in the age 
composition of each STP area. (A) Age distribution of S- and S+ cases. (B) Ratio of S- to S+ 
proportions of cases in each 10 year band. Results shown are for weeks 46-51. Ages were capped 
at 80. 95% empirical confidence intervals calculated by bootstrapping over STP areas and weeks, 
and sampling variation within STP areas and weeks. 
 
 
Regression analysis of VOC transmissibility 
 
To investigate the effect of VOC frequency on the overall time-varying reproduction number, R​t​, 
we undertook a number of regression analyses. We conduct our analyses at two different 
spatial scales - lower tier local authority (LTLA) and NHS STP areas. For each, we estimated R​t 
by week and area using data on pillar 2 testing, deaths and hospitalisations using a previously 
described model ​9,11​. Figure 5 shows the empirical relationship between weekly estimates of R ​t​ at 
STP level and the frequency of the VOC estimates using genomic data. 
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Figure 5: Relationship between genomic frequency of the VOC lineage among all genomes plotted 




We apply a range of frequentist models with a bootstrapping procedure to account for 
non-normality in responses, as well as a Bayesian regression which explicitly models VOC 
frequency, such that it simultaneously informs the parameter for binomially-distributed 
observations of frequency and the R ​t ​estimates. The role of geography in explaining variance of 
R​t ​ was examined using both fixed and random effects. These models were applied to both 
genomic-based frequency estimates and TPR-adjusted SGTF proportions of pillar 2 cases for 
which S-gene data was available. Given this definition and the approximately 1 week generation 
time of SARS-CoV-2, we expect R​t​ to have stronger association with VOC frequency 1 week 
earlier. We therefore present regressions of R ​t​ against frequency at week ​t​-1 for our default 
analysis (where ​t​ spans weeks 44-50), and a regression of R ​t​ against frequency at week ​t​ is 
provided in the Supplementary Information. 
 
Regression results are reported in Table 2 (Table S2 for sensitivity analysis). We estimate the 
additive effect on R ​t​, i.e., the increase or decrease in R ​t​ (using R ​t​ as response in the linear 
model) due to the variant. As an example, with an additive effect size of 0.4, an area with an R​t 
of 0.8 without the VOC would have an R ​t​ of 1.2 if only the VOC was present. As expected, 
models which allow for fixed effects of week and region give lower effect sizes for the VOC than 
random effect models, given the latter constrain week and time effects more than fixed effect 
models, due to the assumptions that such effects arise from normal distributions. The Bayesian 
model results closely resemble those from the frequentist random effects model. 
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The results in Table 2 show a clear association between the VOC and R ​t​. However, this 
analysis cannot prove causality. The estimated additive effect is specific to the conditions that 
prevailed in England during the time period examined.  
 
Table 2. Estimated additive change of reproduction numbers of VOC compared with other variants 
for different regression models, spatial resolutions, and data used to estimate the prevalence of 
the VOC. Analysis uses R​t​ estimates  from weeks 44-50 and data on the proportion of the VOC one 
week earlier, to take account of the generation time of SARS-CoV-2.  
 
 
Estimating reproduction numbers for VOC and non-VOC independently 
 
We estimated the reproduction number of the VOC via phylodynamic analysis of whole genome 
sequences from Pillar 2 national SARS-CoV-2 testing, sampled up to December 6, 2020. First, 
we fitted a non-parametric ​skygrowth ​ model ​12​ by maximum likelihood to 776 genomes that we 
selected from England in inverse proportion to the number of diagnosed cases sequenced in 
each region by week (see Supporting Methods). This model indicates that the effective 
population size of VOC 202012/01 grew at a relatively stable rate of 58% per week from 
September 20  to December 6, corresponding to a reproduction number of 1.59. Estimates of 
growth rate were insensitive to uncertainty in the molecular clock rate of evolution. Second, we 
fitted the model to genomes from four regions with more than fifty sequences, Kent (n=701), 
Greater London (n=606), Essex (n=131), and Norfolk (n=81). This regional analysis indicated 
growth rates ranging from 58% to 92% per week, corresponding to reproduction numbers 
between 1.56 and 1.95 (Figure S6).  ​Finally, we carried out a Bayesian non-parametric coalescent 
analysis using the Skygrid model ​13​ using the same set of ​776 genomes. This analysis showed 
growth until the start of November followed by a plateau for the month of November coincident 
with the second English lockdown (Figure S7). This suggests the lockdown constrained growth 
of the VOC, but was insufficient to cause a reduction in incidence. ​To estimate parameter values 




Data for Variants Estimated effect [95% CI] 
Fixed STP Genomic 0.48 [0.31, 0.85] 
Random STP Genomic 0.67 [0.52, 1.11]  
Bayes STP Genomic 0.68 [0.44, 0.93] 
Fixed LTLA TPR-adjusted SGTF 0.42 [0.33, 0.58] 
Random LTLA TPR-adjusted SGTF 0.52 [0.45, 0.69] 
Fixed  STP TPR-adjusted SGTF 0.36 [0.11, 0.58] 
Random STP TPR-adjusted SGTF 0.47 [0.25, 0.70]  
Bayes STP TPR-adjusted SGTF 0.48 [0.31, 0.63] 
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coalescent model ​14​. Under this model we estimated a growth rate of 71.5 per year, corresponding to 
a doubling time of 3.7 days (95% CrI: 2.4 – 4.9) and a reproduction number of 2.27 (1.84 – 2.73). By 
comparison, a simple exponential growth model over this entire period yields a growth rate of 27.9 
with a doubling time of 9.1 days (7.4, 11.2) and reproductive number of 1.50 (1.40 – 1.60).  
 
In a parallel epidemiological analysis, we estimated VOC and non-VOC pillar 2 case numbers 
by STP area using TPR-corrected SGTF frequencies applied to overall PHE pillar 2 case 
numbers. We then estimate R ​t​ by week separately for VOC and non-VOC, using the same 
model previously used to generate overall (non lineage-stratified) R ​t​ estimates​11​. We first fit the 
unstratified model to estimate the infection ascertainment ratio (numbers of infections being 
identified as positive cases) and infection seeding (initial infections in each region). For seeding, 
we use the estimated infections from our unstratified model. The mean number of daily 
infections for week 42 and 43 are used for seeding both VOC and non-VOC models. The 
fraction of SGTF cases is used to distribute infections for seeding between VOC and non-VOC 
in weeks 42 and 43. We then compute R ​t ​estimates for weeks 45-50, to avoid the seeding 
assumptions affecting R ​t​ estimates. Figure 6A shows the mean posterior difference between R ​t 
estimates for VOC and non-VOC for week 48 and 50, while figure 6B shows plots median R ​t 
estimates for VOC and non-VOC across all NHS regions for weeks 45-50. The R ​t​ estimates for 
VOC are greater than those for non-VOC for 94% of STP-week pairs (points above the diagonal 
in Figure 6B). Figure S4 shows the mean posterior difference between R ​t​ estimates for VOC 
and non-VOC for all weeks 45-50, while Figure S5 shows the ratio of R ​t​ estimates. The mean R ​t 
difference across weeks 45-50 is 0.51 [95% CrI: -0.09 - 1.10] which was computed from the set 
of 42x6 (STP x week) posteriors of R ​t​ estimated for the VOC and non-VOC.​ ​The mean ratio of 
the estimated R ​t​ for the VOC and non-VOC was 1.56 [95%CI: 0.92 - 2.28] for the same period, 
see Figure S5. Aggregating across all STPs we find that the mean R ​t  ​during the second English 
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Figure 6: (A) Map of the difference in median R​t ​ estimates for VOC and non-VOC variants for all 
STPs for weeks 48 and week 50. (B) Scatterplot of the reproduction numbers of VOC (S-) and 
non-VOC (S+) by STP and week. Point size indicates frequency of the VOC, while shape and 





While evidence has accumulated that substitutions associated with the B.1.1.7 lineage are 
associated with significant changes in virus phenotype ​2–4,15​, assessing the extent to which these 
changes lead to meaningful differences in transmission between humans is challenging and 
cannot be evaluated experimentally. When randomised experimental studies are not possible, 
observational studies provide stronger evidence if consistent patterns are seen in multiple 
locations and at multiple times. While rapidly increasing frequency of a new lineage within a viral 
population is consistent with a selective advantage, it is also possible that increases in 
frequency may be caused by founder effects or genetic drift, especially for genetic variants 
which are repeatedly introduced from overseas​16,17​.  But in contrast to previous genetic variants 
which have achieved high prevalence, we see expansion of the VOC from within the United 
Kingdom and a pattern of faster epidemic growth in tandem with expansion of the VOC has 
been repeated in multiple regions.  In this paper we have focussed on spatiotemporally stratified 
analyses using a variety of statistical approaches to evaluate the relationship between 
SARS-CoV-2 transmission intensity and the frequency of the VOC, B.1.1.7 during 
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Assessment of the transmission characteristics of the VOC (B.1.1.7) was aided by the high 
correlation between its frequency and the occurrence of S-gene target failure (SGTF) in routine 
PCR testing of community cases of COVID-19 associated with the Δ69-70 deletion present in 
the VOC lineage (Figure 1 and S1). S-gene positivity results were available for over a third of all 
PCR-positive community COVID-19 cases for November and December 2020, allowing us to 
use SGTF frequency as a proxy for VOC frequency, and thus estimate VOC and non-VOC 
incidence trends by region over that time period. We see a very clear visual association 
between SGTF frequency and epidemic growth in nearly all areas (Figures 2 and S3), which is 
reinforced by empirical assessment of area-specific week on week growth factors of VOC and 
non-VOC case numbers (Figure 3) and by formal regression analyses of the association 
between estimates of local R ​t​ and VOC frequency estimated from SGTF data (Table 2).  
 
Finally, we used the SGTF data to independently estimate R ​t​ by region and week for the VOC 
and non-VOC variants (Figures 6 and S4) and derived similar estimates for the increase in R​t 
associated with the VOC. This latter analysis is perhaps the most powerful, as no parametric 
assumptions are made about the relationship between R ​t​ of the VOC and that of non-VOC 
strains. 
 
Phylodynamic modelling provides additional information about growth of the VOC in October 
during a period when SGTF data is sparse. Although not apparent in all analyses, this suggests 
that the VOC expanded rapidly in October, with growth slowing (but not reversing) during 
national lockdown in November (Figures S6 and S7).  
 
We were also able to rule out the hypothesis that increased incidence growth rates in the VOC 
are solely due to a change in the latent period or generation time distribution, but not the 
reproduction number itself (Table 1), since we see a large and statistically significant imbalance 
between regions where the VOC increased and where the non-VOC decreased, and vice-versa. 
A change solely in, for instance, the latent period would not be expected to change the direction 
of incidence growth.  
 
We quantified the transmission advantage of the VOC relative to non-VOC lineages in two 
ways: as an additive increase in R that ranged between 0.4 and 0.7, and alternatively as a 
multiplicative increase in R that ranged between a 50% and 75% advantage. We were not able 
to distinguish between these two approaches in goodness-of-fit, and either is plausible 
mechanistically. A multiplicative transmission advantage would be expected if transmissibility 
had increased in all settings and individuals, while an additive advantage might reflect increases 
in transmissibility in specific subpopulations or contexts. More generally, the temporal context is 
important; these estimates of transmission advantage apply to a period where high levels of 
social distancing were in place in England; extrapolation to other transmission contexts, without 
detailed knowledge of the drivers of transmission, requires caution.  
 
We observe a small but statistically significant shift towards under 20s being more affected by 
the VOC  than non-VOC variants (Figure 4), even after controlling for variation by week and 
region. However, as with our earlier results, this observation does not resolve the mechanism 
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that might underlie these differences. Differences between the age-distributions of VOC and 
non-VOC community cases  may result from the overall increase in transmissibility of the VOC 
(especially during a time where lockdown was in force but schools were open), increased 
susceptibility of under 20s, or more apparent symptoms (and thus a propensity to seek testing) 
for the VOC in that age range.  
 
There are a number of limitations to our analysis. The genomic and epidemiological data 
analysed was collected as part of routine surveillance, and thus may not be an entirely 
representative sample of SARS-CoV-2 infections in England over the time period considered. 
We also focussed on relatively simple, data-driven analyses using relatively simple models 
making  parsimonious assumptions, rather than, for instance, attempting to model the long-term 
transmission dynamics of VOC and non-VOC lineages more mechanistically. We also did not 
attempt to explicitly model the spatiotemporal correlation intrinsic in infectious disease data, 
especially when considering the spread of a new variant from a point source. Doing so is an 
important priority for future work, but will require explicit incorporation of data on population 
movement patterns.  
 
Early versions of our analyses informed the UK government policy response to this VOC and 
that of other countries. The substantial transmission advantage we have estimated the VOC to 
have over prior viral lineages poses major challenges for ongoing control of COVID-19 in the UK 
and elsewhere in the coming months. Social distancing measures will need to be more stringent 
than they would have otherwise. A particular concern is whether it will be possible to maintain 
control over transmission while allowing schools to reopen in January 2021. These policy 
questions will be informed by the ongoing urgent epidemiological investigation into this variant, 
most notably examining evidence for any changes in severity, but also giving more nuanced 
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All code and data is available at ​https://github.com/mrc-ide/covid19-variant-N501Y 
 
Logistic growth model applied to variant frequency data  
 
The logistic growth model fitted to VOC frequency data arises from a simple mechanistic model 
for competition between two strains. Let established lineages have a reproduction number ​R 
and let the VOC have reproduction number ​R ​(1+​s​). According to this model, the log odds of 
observing a variant over time  will be proportional to ( ​R ​/​g ​)​st​, where ​R ​ is assumed to be constant 
over weeks 44-49, ​g ​ is the generation time, ​s​ is a selection coefficient (assumed to be constant) 
and t is time.  If these conditions are met, s can be interpreted as a multiplicative change in the 
reproduction number ​or ​ as a change in the generation time or as some combination of these 
factors. From available data on times of sampling each variant, the compound parameter ( ​R ​/​g​)​s 
can be estimated. An approximate estimate of ​s ​ is obtained by treating ​ ​R​=1 ​ and generation time 
g ​=6.5 days as a constant for weeks 44-49. In the text, we refer to s as the change in growth ​per 
generation ​, and is comparable to multiplicative changes in ​R ​t​ ​estimated using other methods. 
 
Phylodynamic analysis  
 
Analysis was based on Pillar 2 whole genome sequences with known Upper Tier Local Authority 
(UTLA). Maximum likelihood non-parametric phylodynamic analysis was carried out by: 1) 
estimating a maximum likelihood phylogeny in IQtree ​18​ (HKY model of sequence evolution); 2) 
We removed duplicated identical sequences and estimated a time-scaled phylogeny using 
treedater​19​ using a strict molecular clock. The molecular clock rate of evolution was constrained 
to 0.0005 - 0.0015 substitutions per site per year. Small branch lengths in the tree were 
collapsed and polytomies randomly resolved to produce 20 new variations on the dated ML tree. 
3) The skygrowth model was then fitted to these dated trees with parameters 64 time steps and 
tau bounded between 0.0025-20. Growth rate estimates were translated to reproduction 
numbers using the method of Wallinga and Lipsitch ​20​ in the ​epitrix ​ R package and using serial 
intervals from Flaxman et al.​9​ The main text reports the median growth rate over time. A 
sensitivity analysis was carried out with the molecular clock rate fixed at 0.001 substitutions per 
site per year which yielded only marginally different estimates of the median growth rate.  
 
Sequence sample weights were used to select samples for phylodynamic modelling. Weights, 
assigned to sequence samples according to their UTLA and their collection date, correspond to 
the number of confirmed cases represented by each sequence in a UTLA relative to other 
UTLAs on the same date. To smooth over sparsity, case and sample counts were summed over 
the fourteen days prior to the date. Confirmed cases were accessed from the ONS API 
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Bayesian coalescent phylodynamic analysis was performed using BEAST v1.10.4 ​14​ employing 
the Skygrid non-parametric approach ​21​ and exponential and logistic growth parametric models. 
A Jukes-Cantor model of substitution and a strict molecular clock were assumed. MCMC chains 
were run for 100M states, removing 10M as ‘burn-in’ and then thinning to 9000 samples from 
the posterior. Parameters were summarised and demographic curves reconstructed using 
Tracer v1.7.2 ​22​.  
 
SGTF as a biomarker for the VOC and frequency of SGTF over time  
 
Data on SGTF among pillar 2 tests was obtained from the 3 largest (“Lighthouse”) PCR testing 
laboratories and integrated into the PHE Second Generation Surveillance System (SGSS) 
database. We also obtained the total number of cases reported by Public Health England. 
Application of SGTF as a diagnostic for the VOC provides a large advantage over genomic 
sequencing in terms of cost, speed, and the sample size of available test results. We extracted 
275,571 S target positive (S+) and 96,070 S target negative (S-) test results collected between 1 
October and 19 December, 2020 and examined the potential to use SGTF cases (S-) as a 
biomarker for the VOC lineage. While the tests are not a representative sample of infections 
over this time period, they are a representative sample of tests within a given region and week 
and thus provide information about the relative abundance of the VOC versus other variants 
over time and between regions.  
 
Other lineages have been observed to carry Δ69-70 which is associated with SGTF and which 
would have a similar impact on the TaqPath assay. The diagnostic specificity of SGTF will 
therefore vary over time and space as it depends on the abundance of other lineages with 
Δ69-70. This deletion is mostly found in global lineage B.1.258 and is highly linked with the 
spike N439K variant​23​. Lineage B.1.258 has circulated in the UK since June 2020 where it is 
now widespread. However, the frequency of this variant has been relatively stable since 
October 2020.  
 
In order to capture diagnostic uncertainty with SGTF, we fitted a spatio-temporal model of the 
frequency of the VOC relative to other variants carrying Δ69-70. We fitted a generalized additive 
model ​24,25​ to counts of genomes classified ​26​ as belonging to the VOC lineage or genomes which 
do not belong to the VOC lineage but still carry Δ69-70. Counts were tabulated by LTLA and epi 
week. We used a cubic spline to model trends over time, and correlation between neighbouring 
LTLAs was modeled with a Gaussian Markov Random Field (GMRF). This model was used to 
predict the true positive rate (TPR) - the probability that a sample collected at a particular time 
and place belongs to the VOC lineage, given that it carries  Δ69-70. Figure S1 shows how this 
prediction has changed over weeks spanning November 2020. From week 50 onwards, we 
assumed the TPR was 1 across England. The fitted model thus provided an estimate of the true 
positive rate (TPR) of using SGTF as a proxy for VOC frequency as a function of time and 
region in England (Figure S2).  
 
Regression analysis of VOC transmissibility 
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Using reported COVID-19 PCR-positive case counts and deaths, we estimated the time-varying 
reproduction numbers R ​t​ for epidemiological weeks 44-50 in each LTLA and STP in England. 
These estimates were obtained from a previously developed ​11​ Bayesian semi-mechanistic 
transmission model with a latent weekly random walk process that does not include underlying 
factors that drive transmission. The STP model is based on pillar 2 cases only, and includes 
hospital admissions as an additional input; the LTLA model is based on both pillar 1 and pillar 2 
data. Further model information can be found in previous publications ​9,27​. These R ​t​ estimates 
refer to the reproduction number of the infections that gave rise to the infections at time ​t ​. Given 
this definition and the approximately 1 week generation time of SARS-CoV-2, we would expect 
R​t​ to be most closely associated with VOC frequency 1 week earlier. We therefore present 
regressions of R ​t​ against frequency at week ​t​-1 for our default analysis (where ​t​ spans weeks 
44-50), but present results for regression of R ​t​ against frequency at week ​t​ as a sensitivity 
analysis in Supplementary Information. 
 
We consider two data sources when estimating the proportion of the VOC: Genomic-based 
frequency estimates and TPR-adjusted SGTF proportions of pillar 2 cases for which S-gene 
data was available. For the SGTF-based estimates, frequency estimates were available for all 
STPs and LTLAs for the weeks 43-49 (294 STP-weeks in total). When using genomic data, 7 
STP-weeks in the week range 43-49 had no sampled genomes, leaving 287 STP-weeks for 
analysis, for which we had an average of 137 genomes per STP week (of which on average 7 
were the VOC).  
 
We use two types of frequentist models. The first uses a fixed effect for each area, the second 
uses a random effect for each area. Fixed effects of epidemiological week were included in both 
cases. Confidence intervals for the fixed and random effects models were computed through a 
bootstrapping method which resamples the areas with replacement and also samples the 
counts of VOC in each week/area pair based on the observed counts. This bootstrap aims to 
account for potential skewness and non-normality of responses, dependence within areas and 
the randomness in the proportion of the VOC sampled within an area. When using 
genomic-based frequency estimates we excluded STP-weeks that had fewer than 5 genetic 
profiles, as these were deemed to not give reliable estimates of the proportion of VOC. This 
removed a further ​14 out of the 287 ​ STP-weeks from those analyses.  
 
We also implemented a Bayesian regression model ​28​ at STP level, taking into account 
uncertainty in the frequency estimates and uncertainty in the R ​t​ estimates. VOC frequency was 
modelled explicitly, such that it simultaneously informed the parameter for binomially-distributed 
observations of frequency and the R ​t ​estimates. The regression for R ​t​ included terms for the 
VOC frequency, the week (modelled with a smooth spline) and the area as a factor. The formula 
to describe the binomial frequency data includes a linear function of time with an 
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Table S1.  Estimated growth difference per generation of B.1.1.7 by 
English administrative region based on a maximum likelihood estimation 
of logistic growth in variant frequency and assuming a 6.5 day generation 
time and R​t​=1 for established lineages. Confidence intervals are based on 
likelihood profiles 
 MLE %Growth difference 





South East 49 (43-55) 54 
London 49 (43-54) 60 
East of England 53 (44-62) 67 
West Midlands  59 
East Midlands  56 
North West  58 
Yorkshire and  
The Humber 
 40 
North East  75 
South West   48 
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Table S2. Estimated additive change of reproduction numbers of VOC compared with non-VOC 
using different regression models, spatial resolutions, and data to estimate the prevalence of the 






Data for Variants Estimated effect [95% CI] 
Fixed STP Genomic 0.34 [0.16, 0.60] 
Random STP Genomic 0.52 [0.35, 0.85] 
Bayes STP Genomic 0.54 [0.33, 0.77] 
Fixed LTLA TPR-adjusted SGTF 0.45 [0.40, 0.59] 
Random LTLA TPR-adjusted SGTF 0.53 [0.49, 0.67] 
Fixed  STP TPR-adjusted SGTF 0.35 [0.15, 0.56] 
Random STP TPR-adjusted SGTF 0.44 [0.27, 0.65] 
Bayes STP TPR-adjusted SGTF 0.43 [0.30, 0.56] 
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Figure S1 | Estimate of true positive rates for classification of B.1.1.7 infection given SGTF 
result (S-) as a function of time and UK region. The colour gradient shows the probability of 
sampling a B.1.1.7 sequence conditional on sampling any sequence with Δ69-70.  
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Figure S2. Empirical (point) and estimated (line) frequencies of TPR-adjusted SGTF frequencies 
over time. The size of points correspond to the number of samples observed by day. 
Confidence intervals show 95% estimated sampling error for daily proportions. 
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Figure S3. Case trends in all NHS STP areas, ordered by decreasing frequency of S- in the last 
week shown. Total cases reported are shown as a thick line. A subset of these - those tested in 
the 3 largest “Lighthouse” laboratories - were tested for SGTF. The total cases line is coloured 
according to percentage S- among those tested. Counts of S+ and S- reported via the PHE 
SGSS system are shown by the thin lines. The dates of the second lockdown are indicated by 
the vertical red lines. Raw SGTF data are shown here (not adjusted for TPR), so S- cases in 
earlier weeks include other non-VOC lineages, especially outside the East and South East of 
England. 
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Figure S4:  Map of the  difference in median Rt estimates for VOC and non-VOC variants for all 
STPs between week 45 to week 50. The darker orange color indicates the additive advantage 
VOC has over non-VOC variant for Rt, whereas the darker green color shows the advantage for 
non-VOC variant over VOC.  
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Figure S5. Map of the ratio of median Rt estimates for VOC and non-VOC variants for all STPs 
between week 45 to week 50. Darker color indicates the higher multiplicative advantage for VOC 
variant in comparison to the non-VOC variant. The mean of the ratio between R estimates for S- 




1 We calculated this as the posterior mean and 2.5-97.5 quantiles of the set of 42x6 posterior medians of 
the distributions (R_{S-} - R_{S+}), one per STP-week 
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Figure S6.  Maximum likelihood ​skygrowth​ estimates of the effective population size of the VOC 
through time in England and in four areas of England with more than 80 whole genome 
sequences. In the upper right panel the molecular clock rate of evolution was fixed at 0.001 
substitutions per site per year. In all other analyses the rate was estimated and bound between 
0.0005 and 0.0015 substitutions per site per year.  
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Figure S7. Bayesian estimates of effective population size through time based on 776 genomes 
sampled between October and December 6. Top and bottom panels show estimates based on a 
Bayesian skygrid model overlaid with fits of different parametric models. A) Estimates based on 
a logistic growth model. B) Estimates from an exponential growth model.  
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Leadership and supervision,​ ​Metadata curation,​ ​Project administration, and Samples and 
logistics: 
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Dr Samuel Moses ​25, ​ ​106 ​. 
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Prof Darren L Smith ​37, ​ ​58, ​ ​105 ​. 
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tools: 
Dr Matthew D Parker ​93 ​. 
  
Metadata curation,​ ​Samples and logistics,​ ​Sequencing and analysis, and Visualisation: 
Dr Sharon Glaysher ​61 ​. 
  
Metadata curation,​ ​Sequencing and analysis,​ ​Software and analysis tools, and Visualisation: 
Dr Matthew Bashton ​37, ​ ​58 ​, Dr Anthony P Underwood ​14, ​ ​114 ​, Dr Nicole Pacchiarini ​69 ​ and Dr Katie F 
Loveson ​77 ​. 
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Dr Alessandro M Carabelli ​88 ​. 
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Dr Kate E Templeton ​53, ​ ​90 ​. 
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Dr Cordelia F Langford ​99 ​, John Sillitoe ​99 ​, Dr Thushan I de Silva ​93 ​ and Dr Dennis Wang ​93 ​. 
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Dr Mara Lawniczak ​99 ​. 
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Oliver G Pybus ​23 ​. 
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Metadata curation,​ ​Project administration, and Samples and logistics: 
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Stefan Rooke ​90 ​ and Dr Sharif Shaaban ​68 ​. 
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Samples and logistics,​ ​Sequencing and analysis, and Software and analysis tools: 
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Sequencing and analysis,​ ​Software and analysis tools, and Visualisation: 
Áine O'Toole ​90 ​, Dr Andrew R Hesketh ​87 ​, Mr Richard Stark ​94 ​, Dr Louis du Plessis ​23 ​, Dr Chris Ruis ​88 ​, Dr 
Helen Adams ​4 ​ and Dr Yann Bourgeois ​76 ​. 
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Dr Naomi R Park ​99 ​, Karen Oliver ​99 ​, Dr Aaron R Jeffries ​91 ​, Dr Sascha Ott ​94 ​, Dr Ana da Silva Filipe ​48 ​, Dr 
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Casey ​71 ​, Dr Andrew Bosworth ​64, ​ ​36 ​, Dr Liz Ratcliffe ​71 ​, Dr Li Xu-McCrae ​36 ​, Miss Hannah M Pymont ​64 ​, Ms 
Stephanie Hutchings ​64 ​, Dr Lisa Berry ​84 ​, Ms Katie Jones ​84 ​, Dr Fenella Halstead ​46 ​, Mr Thomas Davis ​21 ​, 
Dr Christopher Holmes ​16 ​, Prof Miren Iturriza-Gomara ​92 ​, Dr Anita O Lucaci ​92 ​, Dr Paul Anthony Randell ​38, 
104 ​, Dr Alison Cox ​38, ​ ​104 ​, Pinglawathee Madona ​38, ​ ​104 ​, Dr Kathryn Ann Harris ​30 ​, Dr Julianne Rose Brown ​30 ​, 
Dr Tabitha W Mahungu ​74 ​, Dr Dianne Irish-Tavares ​74 ​, Dr Tanzina Haque ​74 ​, Dr Jennifer Hart ​74 ​, Mr Eric 
Witele ​74 ​, Mrs Melisa Louise Fenton ​75 ​, Mr Steven Liggett ​79 ​, Dr Clive Graham ​56 ​, Ms Emma Swindells ​57 ​, 
Ms Jennifer Collins ​50 ​, Mr Gary Eltringham ​50 ​, Ms Sharon Campbell ​17 ​, Dr Patrick C McClure ​97 ​, Dr Gemma 
Clark ​15 ​, Dr Tim J Sloan ​60 ​, Mr Carl Jones ​15 ​ and Dr Jessica Lynch ​2,​ ​111 ​. 
  
Metadata curation, and Sequencing and analysis: 
Dr Ben Warne ​8 ​, Steven Leonard ​99 ​, Jillian Durham ​99 ​, Dr Thomas Williams ​90 ​, Dr Sam T Haldenby ​92 ​, Dr 
Nathaniel Storey ​30 ​, Dr Nabil-Fareed Alikhan ​70 ​, Dr Nadine Holmes ​18 ​, Dr Christopher Moore ​18 ​, Mr 
Matthew Carlile ​18 ​, Malorie Perry ​69 ​, Dr Noel Craine ​69 ​, Prof Ronan A Lyons ​80 ​, Miss Angela H Beckett ​13 ​, 
Salman Goudarzi ​77 ​, Christopher Fearn ​77 ​, Kate Cook ​77 ​, Hannah Dent ​77 ​ and Hannah Paul ​77 ​. 
  
Metadata curation, and Software and analysis tools: 
Robert Davies ​99 ​. 
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Beth Blane ​88 ​, Sophia T Girgis ​88 ​, Dr Mathew A Beale ​99 ​, Katherine L Bellis ​99, ​ ​88 ​, Matthew J Dorman ​99 ​, 
Eleanor Drury ​99 ​, Leanne Kane ​99 ​, Sally Kay ​99 ​, Dr Samantha McGuigan ​99 ​, Dr Rachel Nelson ​99 ​, Liam 
Prestwood ​99 ​, Dr Shavanthi Rajatileka ​99 ​, Dr Rahul Batra ​12 ​, Dr Rachel J Williams ​82 ​, Dr Mark Kristiansen 
82 ​, Dr Angie Green ​98 ​, Miss Anita Justice ​59 ​, Dr Adhyana I.K Mahanama ​81, ​ ​102 ​ and Dr Buddhini 
Samaraweera ​81, ​ ​102 ​. 
  
Project administration, and Sequencing and analysis: 
Dr Nazreen F Hadjirin ​88 ​ and Dr Joshua Quick ​41 ​. 
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Mr Radoslaw Poplawski ​41 ​. 
  
Samples and logistics, and Sequencing and analysis: 
Leanne M Kermack ​88 ​, Nicola Reynolds ​7 ​, Grant Hall ​24 ​, Yasmin Chaudhry ​24 ​, Malte L Pinckert ​24 ​, Dr Iliana 
Georgana ​24 ​, Dr Robin J Moll ​99 ​, Dr Alicia Thornton ​66 ​, Dr Richard Myers ​66 ​, Dr Joanne Stockton ​41 ​, Miss 
Charlotte A Williams ​82 ​, Dr Wen C Yew ​58 ​, Alexander J Trotter ​70 ​, Miss Amy Trebes ​98 ​, Mr George 
MacIntyre-Cockett ​98 ​, Alec Birchley ​69 ​, Alexander Adams ​69 ​, Amy Plimmer ​69 ​, Bree Gatica-Wilcox ​69 ​, Dr 
Caoimhe McKerr ​69 ​, Ember Hilvers ​69 ​, Hannah Jones ​69 ​, Dr Hibo Asad ​69 ​, Jason Coombes ​69 ​, Johnathan M 
Evans ​69 ​, Laia Fina ​69 ​, Lauren Gilbert ​69 ​, Lee Graham ​69 ​, Michelle Cronin ​69 ​, Sara 
Kumziene-SummerhaYes ​69 ​, Sarah Taylor ​69 ​, Sophie Jones ​69 ​, Miss Danielle C Groves ​93 ​, Mrs Peijun 
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Samples and logistics, and Software and analysis tools: 
Dr Igor Starinskij ​48 ​. 
  
Sequencing and analysis, and Software and analysis tools: 
Dr Chris J Illingworth ​47 ​, Dr Chris Jackson ​47 ​, Ms Marina Gourtovaia ​99 ​, Gerry Tonkin-Hill ​99 ​, Kevin Lewis ​99 ​, 
Dr Jaime M Tovar-Corona ​99 ​, Dr Keith James ​99 ​, Dr Laura Baxter ​94 ​, Dr Mohammad T. Alam ​94 ​, Dr Richard 
J Orton ​48 ​, Dr Joseph Hughes ​48 ​, Dr Sreenu Vattipally ​48 ​, Dr Manon Ragonnet-Cronin ​39 ​, Dr Fabricia F. 
Nascimento ​39 ​, Mr David Jorgensen ​39 ​, Ms Olivia Boyd ​39 ​, Ms Lily Geidelberg ​39 ​, Dr Alex E Zarebski ​23 ​, Dr 
Jayna Raghwani ​23 ​, Dr Moritz UG Kraemer ​23 ​, Joel Southgate ​10, ​ ​69 ​, Dr Benjamin B Lindsey ​93 ​ and Mr 
Timothy M Freeman ​93 ​. 
  
Software and analysis tools, and Visualisation: 
Jon-Paul Keatley ​99 ​, Dr Joshua B Singer ​48 ​, Leonardo de Oliveira Martins ​70 ​, Dr Corin A Yeats ​14 ​, Dr Khalil 
Abudahab ​14, ​ ​114 ​, Mr Ben EW Taylor ​14, ​ ​114 ​ and Mirko Menegazzo ​14 ​. 
  
Leadership and supervision: 
Prof John Danesh ​99 ​, Wendy Hogsden ​46 ​, Dr Sahar Eldirdiri ​21 ​, Mrs Anita Kenyon ​21 ​, Dr Jenifer Mason ​43 ​, 
Mr Trevor I Robinson ​43 ​, Prof Alison Holmes ​38, ​ ​103 ​, Dr James Price ​38, ​ ​103 ​, Prof John A Hartley ​82 ​, Dr Tanya 
Curran ​3 ​, Dr Alison E Mather ​70 ​, Dr Giri Shankar ​69 ​, Dr Rachel Jones ​69 ​, Dr Robin Howe ​69 ​ and Dr Sian 
Morgan ​9 ​. 
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Dr Elizabeth Wastenge ​53 ​, Dr Michael R Chapman ​34, ​ ​88, ​ ​99 ​, Mr Siddharth Mookerjee ​38, ​ ​103 ​, Dr Rachael 
Stanley ​54 ​, Mrs Wendy Smith ​15 ​, Prof Timothy Peto ​59 ​, Dr David Eyre ​59 ​, Dr Derrick Crook ​59 ​, Dr Gabrielle 
Vernet ​33 ​, Dr Christine Kitchen ​10 ​, Huw Gulliver ​10 ​, Dr Ian Merrick ​10 ​, Prof Martyn Guest ​10 ​, Robert Munn ​10 ​, 
Dr Declan T Bradley ​63, ​ ​72 ​, and Dr Tim Wyatt ​63 ​. 
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Dr Charlotte Beaver ​99 ​, Luke Foulser ​99 ​, Sophie Palmer ​88 ​, Carol M Churcher ​88 ​, Ellena Brooks ​88 ​, Kim S 
Smith ​88 ​, Dr Katerina Galai ​88 ​, Georgina M McManus ​88 ​, Dr Frances Bolt ​38, ​ ​103 ​, Dr Francesc Coll ​19 ​, Lizzie 
Meadows ​70 ​, Dr Stephen W Attwood ​23 ​, Dr Alisha Davies ​69 ​, Elen De Lacy ​69 ​, Fatima Downing ​69 ​, Sue 
Edwards ​69 ​, Dr Garry P Scarlett ​76 ​, Mrs Sarah Jeremiah ​83 ​ and Dr Nikki Smith ​93 ​. 
  
Samples and logistics: 
Danielle Leek ​88 ​, Sushmita Sridhar ​88, ​ ​99 ​, Sally Forrest ​88 ​, Claire Cormie ​88 ​, Harmeet K Gill ​88 ​, Joana Dias ​88 ​, 
Ellen E Higginson ​88 ​, Mailis Maes ​88 ​, Jamie Young ​88 ​, Michelle Wantoch ​7 ​, Sanger Covid Team 
(www.sanger.ac.uk/covid-team) ​99 ​, Dorota Jamrozy ​99 ​, Stephanie Lo ​99 ​, Dr Minal Patel ​99 ​, Verity Hill ​90 ​, Ms 
Claire M Bewshea ​91 ​, Prof Sian Ellard ​73, ​ ​91 ​, Dr Cressida Auckland ​73 ​, Dr Ian Harrison ​66 ​, Dr Chloe Bishop 
66 ​, Dr Vicki Chalker ​66 ​, Dr Alex Richter ​85 ​, Dr Andrew Beggs ​85 ​, Dr Angus Best ​86 ​, Dr Benita Percival ​86 ​, Dr 
Jeremy Mirza ​86 ​, Dr Oliver Megram ​86 ​, Dr Megan Mayhew ​86 ​, Dr Liam Crawford ​86 ​, Dr Fiona Ashcroft ​86 ​, Dr 
Emma Moles-Garcia ​86 ​, Dr Nicola Cumley ​86 ​, Mr Richard Hopes ​64 ​, Dr Patawee Asamaphan ​48 ​, Mr Marc O 
Niebel ​48 ​, Prof Rory N Gunson ​100 ​, Dr Amanda Bradley ​52 ​, Dr Alasdair Maclean ​52 ​, Dr Guy Mollett ​52 ​, Dr 
Rachel Blacow ​52 ​, Mr Paul Bird ​16 ​, Mr Thomas Helmer ​16 ​, Miss Karlie Fallon ​16 ​, Dr Julian Tang ​16 ​, Dr 
Antony D Hale ​49 ​, Dr Louissa R Macfarlane-Smith ​49 ​, Katherine L Harper ​49 ​, Miss Holli Carden ​49 ​, Dr 
Nicholas W Machin ​45, ​ ​64 ​, Ms Kathryn A Jackson ​92 ​, Dr Shazaad S Y Ahmad ​45, ​ ​64 ​, Dr Ryan P George ​45 ​, Dr 
Lance Turtle ​92 ​, Mrs Elaine O'Toole ​43 ​, Mrs Joanne Watts ​43 ​, Mrs Cassie Breen ​43 ​, Mrs Angela Cowell ​43 ​, 
Ms Adela Alcolea-Medina ​32, ​ ​96 ​, Ms Themoula Charalampous ​12, ​ ​42 ​, Amita Patel ​11 ​, Dr Lisa J Levett ​35 ​, Dr 
Judith Heaney ​35 ​, Dr Aileen Rowan ​39 ​, Prof Graham P Taylor ​39 ​, Dr Divya Shah ​30 ​, Miss Laura Atkinson ​30 ​, 
Mr Jack CD Lee ​30 ​, Mr Adam P Westhorpe ​82 ​, Dr Riaz Jannoo ​82 ​, Dr Helen L Lowe ​82 ​, Miss Angeliki 
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Karamani ​82 ​, Miss Leah Ensell ​82 ​, Mrs Wendy Chatterton ​35 ​, Miss Monika Pusok ​35 ​, Mrs Ashok Dadrah ​75 ​, 
Miss Amanda Symmonds ​75 ​, Dr Graciela Sluga ​44 ​, Dr Zoltan Molnar ​72 ​, Mr Paul Baker ​79 ​, Prof Stephen 
Bonner ​79 ​, Ms Sarah Essex ​79 ​, Dr Edward Barton ​56 ​, Ms Debra Padgett ​56 ​, Ms Garren Scott ​56 ​, Ms Jane 
Greenaway ​57 ​, Dr Brendan AI Payne ​50 ​, Dr Shirelle Burton-Fanning ​50 ​, Dr Sheila Waugh ​50 ​, Dr Veena 
Raviprakash ​17 ​, Ms Nicola Sheriff ​17 ​, Ms Victoria Blakey ​17 ​, ms Lesley-Anne Williams ​17 ​, Dr Jonathan 
Moore ​27 ​, Ms Susanne Stonehouse ​27 ​, Dr Louise Smith ​55 ​, Dr Rose K Davidson ​89 ​, Dr Luke Bedford ​26 ​, Dr 
Lindsay Coupland ​54 ​, Ms Victoria Wright ​18 ​, Dr Joseph G Chappell ​97 ​, Dr Theocharis Tsoleridis ​97 ​, Prof 
Jonathan Ball ​97 ​, Mrs Manjinder Khakh ​15 ​, Dr Vicki M Fleming ​15 ​, Dr Michelle M Lister ​15 ​, Dr Hannah C 
Howson-Wells ​15 ​, Dr Louise Berry ​15 ​, Dr Tim Boswell ​15 ​, Dr Amelia Joseph ​15 ​, Dr Iona Willingham ​15 ​, Dr 
Nichola Duckworth ​60 ​, Dr Sarah Walsh ​60 ​, Dr Emma Wise ​2,​ ​111 ​, Dr Nathan Moore ​2,​ ​111 ​, Miss Matilde Mori ​2, 
108, ​ ​111 ​, Dr Nick Cortes ​2,​ ​111 ​, Dr Stephen Kidd ​2,​ ​111 ​, Dr Rebecca Williams ​33 ​, Laura Gifford ​69 ​, Miss Kelly 
Bicknell ​61 ​, Dr Sarah Wyllie ​61 ​, Miss Allyson Lloyd ​61 ​, Mr Robert Impey ​61 ​, Ms Cassandra S Malone ​6 ​, Mr 
Benjamin J Cogger ​6 ​, Nick Levene ​62 ​, Lynn Monaghan ​62 ​, Dr Alexander J Keeley ​93 ​, Dr David G Partridge 
78, ​ ​93 ​, Dr Mohammad Raza ​78, ​ ​93 ​, Dr Cariad Evans ​78, ​ ​93 ​ and Dr Kate Johnson ​78, ​ ​93 ​. 
   
Sequencing and analysis: 
Emma Betteridge ​99 ​, Ben W Farr ​99 ​, Scott Goodwin ​99 ​, Dr Michael A Quail ​99 ​, Carol Scott ​99 ​, Lesley Shirley 
99 ​, Scott AJ Thurston ​99 ​, Diana Rajan ​99 ​, Dr Iraad F Bronner ​99 ​, Louise Aigrain ​99 ​, Dr Nicholas M Redshaw 
99 ​, Dr Stefanie V Lensing ​99 ​, Shane McCarthy ​99 ​, Alex Makunin ​99 ​, Dr Carlos E Balcazar ​90 ​, Dr Michael D 
Gallagher ​90 ​, Dr Kathleen A Williamson ​90 ​, Thomas D Stanton ​90 ​, Ms Michelle L Michelsen ​91 ​, Ms Joanna 
Warwick-Dugdale ​91 ​, Dr Robin Manley ​91 ​, Ms Audrey Farbos ​91 ​, Dr James W Harrison ​91 ​, Dr Christine M 
Sambles ​91 ​, Dr David J Studholme ​91 ​, Dr Angie Lackenby ​66 ​, Dr Tamyo Mbisa ​66 ​, Dr Steven Platt ​66 ​, Mr 
Shahjahan Miah ​66 ​, Dr David Bibby ​66 ​, Dr Carmen Manso ​66 ​, Dr Jonathan Hubb ​66 ​, Dr Gavin Dabrera ​66 ​, Dr 
Mary Ramsay ​66 ​, Dr Daniel Bradshaw ​66 ​, Dr Ulf Schaefer ​66 ​, Dr Natalie Groves ​66 ​, Dr Eileen Gallagher ​66 ​, 
Dr David Lee ​66 ​, Dr David Williams ​66 ​, Dr Nicholas Ellaby ​66 ​, Hassan Hartman ​66 ​, Nikos Manesis ​66 ​, Vineet 
Patel ​66 ​, Juan Ledesma ​67 ​, Ms Katherine A Twohig ​67 ​, Dr Elias Allara ​64, ​ ​88 ​, Ms Clare Pearson ​64, ​ ​88 ​, Mr 
Jeffrey K. J. Cheng ​94 ​, Dr Hannah E. Bridgewater ​94 ​, Ms Lucy R. Frost ​94 ​, Ms Grace Taylor-Joyce ​94 ​, Dr 
Paul E Brown ​94 ​, Dr Lily Tong ​48 ​, Ms Alice Broos ​48 ​, Mr Daniel Mair ​48 ​, Mrs Jenna Nichols ​48 ​, Dr Stephen N 
Carmichael ​48 ​, Dr Katherine L Smollett ​40 ​, Dr Kyriaki Nomikou ​48 ​, Dr Elihu Aranday-Cortes ​48 ​, Ms Natasha 
Johnson ​48 ​, Dr Seema Nickbakhsh ​48, ​ ​68 ​, Dr Edith E Vamos ​92 ​, Dr Margaret Hughes ​92 ​, Dr Lucille Rainbow 
92 ​, Mr Richard Eccles ​92 ​, Ms Charlotte Nelson ​92 ​, Dr Mark Whitehead ​92 ​, Dr Richard Gregory ​92 ​, Mr 
Matthew Gemmell ​92 ​, Ms Claudia Wierzbicki ​92 ​, Ms Hermione J Webster ​92 ​, Ms Chloe L Fisher ​28 ​, Mr 
Adrian W Signell ​20 ​, Dr Gilberto Betancor ​20 ​, Mr Harry D Wilson ​20 ​, Dr Gaia Nebbia ​12 ​, Dr Flavia Flaviani ​31 ​, 
Mr Alberto C Cerda ​96 ​, Ms Tammy V Merrill ​96 ​, Rebekah E Wilson ​96 ​, Mr Marius Cotic ​82 ​, Miss Nadua 
Bayzid ​82 ​, Dr Thomas Thompson ​72 ​, Dr Erwan Acheson ​72 ​, Prof Steven Rushton ​51 ​, Prof Sarah O'Brien ​51 ​, 
David J Baker ​70 ​, Steven Rudder ​70 ​, Alp Aydin ​70 ​, Dr Fei Sang ​18 ​, Dr Johnny Debebe ​18 ​, Dr Sarah Francois 
23 ​, Dr Tetyana I Vasylyeva ​23 ​, Dr Marina Escalera Zamudio ​23 ​, Mr Bernardo Gutierrez ​23 ​, Dr Angela 
Marchbank ​10 ​, Joshua Maksimovic ​9 ​, Karla Spellman ​9 ​, Kathryn McCluggage ​9 ​, Dr Mari Morgan ​69 ​, Robert 
Beer ​9 ​, Safiah Afifi ​9 ​, Trudy Workman ​10 ​, William Fuller ​10 ​, Catherine Bresner ​10 ​, Dr Adrienn Angyal ​93 ​, Dr 
Luke R Green ​93 ​, Dr Paul J Parsons ​93 ​, Miss Rachel M Tucker ​93 ​, Dr Rebecca Brown ​93 ​ and Mr Max 
Whiteley ​93 ​. 
  
Software and analysis tools: 
James Bonfield ​99 ​, Dr Christoph Puethe ​99 ​, Mr Andrew Whitwham ​99 ​, Jennifier Liddle ​99 ​, Dr Will Rowe ​41 ​, Dr 
Igor Siveroni ​39 ​, Dr Thanh Le-Viet ​70 ​ and Amy Gaskin ​69 ​. 
  
Visualisation: 
Dr Rob Johnson ​39 ​. 
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1 ​ Barking, Havering and Redbridge University Hospitals NHS Trust, ​2 ​ Basingstoke Hospital, ​3 ​ Belfast 
Health & Social Care Trust, ​4 ​ Betsi Cadwaladr University Health Board, ​5 ​ Big Data Institute, Nuffield 
Department of Medicine, University of Oxford, ​6​ Brighton and Sussex University Hospitals NHS Trust, ​7 
Cambridge Stem Cell Institute, University of Cambridge, ​8​ Cambridge University Hospitals NHS 
Foundation Trust, ​9 ​ Cardiff and Vale University Health Board, ​10​ Cardiff University, ​11​ Centre for Clinical 
Infection & Diagnostics Research, St. Thomas' Hospital and Kings College London, ​12​ Centre for Clinical 
Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS 
Foundation Trust, ​13​ Centre for Enzyme Innovation, University of Portsmouth (PORT), ​14​ Centre for 
Genomic Pathogen Surveillance, University of Oxford, ​15 ​ Clinical Microbiology Department, Queens 
Medical Centre, ​16 ​ Clinical Microbiology, University Hospitals of Leicester NHS Trust, ​17 ​ County Durham 
and Darlington NHS Foundation Trust, ​18 ​ Deep Seq, School of Life Sciences, Queens Medical Centre, 
University of Nottingham, ​19​ Department of Infection Biology, Faculty of Infectious & Tropical Diseases, 
London School of Hygiene & Tropical Medicine, ​20 ​ Department of Infectious Diseases, King's College 
London, ​21​ Department of Microbiology, Kettering General Hospital, ​22 ​ Departments of Infectious 
Diseases and Microbiology, Cambridge University Hospitals NHS Foundation Trust; Cambridge, UK, ​23 
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